Nemolizumab (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "Nemolizumab" in English language version.
refsWebsite
Global rank
English rank
1st place
1st place
low place
low place
615th place
407th place
low place
low place
102nd place
76th place
businesswire.com
- "Galderma Receives U.S. FDA Approval for Nemluvio (nemolizumab) for Adult Patients Living With Prurigo Nodularis" (Press release). Galderma. 13 August 2024. Retrieved 14 August 2024 – via Business Wire.
europa.eu
ema.europa.eu
- "Nemluvio EPAR". European Medicines Agency (EMA). 12 December 2024. Retrieved 13 December 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
fda.gov
fda.gov
- "Drug Trials Snapshots: Nemluvio". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 31 October 2024.
This article incorporates text from this source, which is in the public domain. - "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.
- New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.
- "CY 2024 CDER Breakthrough Therapy Calendar Year Approvals" (PDF). U.S. Food and Drug Administration (FDA). 30 September 2024.
accessdata.fda.gov
- "Drug Approval Package: Nemluvio". U.S. Food and Drug Administration (FDA). 10 September 2024. Retrieved 13 December 2024.
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761391s000lbl.pdf
galderma.com
- "CHMP recommends approval of Galderma's nemolizumab for moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union". Galderma (Press release). 13 December 2024. Retrieved 13 December 2024.
handle.net
hdl.handle.net
- World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 74". WHO Drug Information. 29 (3). hdl:10665/331070.
nih.gov
dailymed.nlm.nih.gov
- "Nemluvio- nemolizumab-ilto injection, powder, lyophilized, for solution". DailyMed. 13 August 2024. Retrieved 5 September 2024.
pharmabiz.com
- "Chugai grants exclusive global license for development and marketing of nemolizumab to Galderma". Pharmabiz.com. 22 July 2016.
web.archive.org
- New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.